BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): RBC Capital recommends owning shares of BioMarin Pharmaceutical Inc. into the binary GALNS readout as they see a 60% chance of the stock reaching $45-$50 following the data. Following negative data, the firm recommends buying the stock on any weakness as they see multiple catalysts for their shares in 2013. The firm maintains an Outperform rating on their stocks.
Bally Technologies, Inc. (NYSE:BYI): Following solid first quarter earnings, Brean Capital raised their price target on Bally Technologies, Inc. The firm expects execution across all segments to continue, sees growth opportunities in high margin businesses, and steady ship share gains. Shares are Buy rated.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Avnet Inc. (NYSE:AVT): Following third quarter results that cited valuation and the necessity of the next quarter producing solid results to drive the stock, Brean Capital lowered their price target on Avnet Inc. Shares remain Buy rated.
Range Resources Corporation (NYSE:RRC): Following solid third quarter results that cited improving IB rates and EUR’s in Southwest Pennsylvania and encouraging data from the company’s Mississippi, Permian, and Utica plays, Brean Capital raised their price target on Range Resources Corporation. Shares are Buy rated.
Constant Contact, Inc. (NASDAQ:CTCT): Cowen said the risk/reward for Constant Contact, Inc. remains favorable in spite of disappointing guidance following their third quarter results. The firm believes that the secular growth opportunity to sell technology down market is intact. Shares remain Outperform rated.
Don’t Miss: Here’s What Put Yelp on a Roller Coaster.